Document is current
Any future updates will be listed below
-
Authors
Gérard, Baptiste
Leask, Megan
Merriman, Tony R. https://orcid.org/0000-0003-0844-8726
Bardin, Thomas
Oehler, Erwan
Lawrence, Aniva
Viali, Satupaitea https://orcid.org/0000-0002-4829-8403
‘Ofanoa, Samuela
Te Karu, Leanne
Stamp, Lisa K. https://orcid.org/0000-0003-0138-2912
Dalbeth, Nicola https://orcid.org/0000-0003-4632-4476
Pascart, Tristan https://orcid.org/0000-0002-8395-826X
- License Information
-
More Information
Article History
Accepted: 7 February 2025
First Online: 11 March 2025
Competing interests
: N.D. has received consulting fees, speaker fees or grants from Aristea, Arthrosi, AstraZeneca, Avalo, Biomarin, Dexcel Pharma, Hikma, Horizon, JPI, JW Pharmaceutical Corporation, LG Chem, Novartis, PK Med, Protalix, PTC Therapeutics, Selecta, Shanton Pharma, Sobi and Unlocked Labs. T.R.M. has received research funding and consulting fees from Variant Bio. L.K.S. has received research funding from the New Zealand Health Research Council and consulting fees from Pharmac outside the submitted work. T.P. has received research funding from Variant Bio and honorary and consulting fees from Horizon Pharmaceuticals and Novartis, unrelated to this work. B.G., M.L., T.B., L.T.K., S.O., S.V., A.L. and E.O. declare no competing interests.
